Nurix Therapeutics, Inc.
NRIX · NASDAQ
11/30/2024 | 11/30/2023 | 11/30/2022 | 11/30/2021 | |
|---|---|---|---|---|
| Market Cap | $1 | $0 | $1 | $1 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $1 | $0 | $1 | $1 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | -29.1% | 99.3% | 29.8% | – |
| Gross Profit | -$0 | -$0 | -$0 | -$0 |
| % Margin | -306.3% | -145.7% | -377.6% | -291.4% |
| EBITDA | -$0 | -$0 | -$0 | -$0 |
| % Margin | -375.8% | -193.4% | -465.3% | -389.6% |
| Net Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | -354.9% | -187% | -466.9% | -393.9% |
| EPS Diluted | -2.88 | -2.65 | -3.71 | -2.73 |
| % Growth | -8.7% | 28.6% | -35.9% | – |
| Operating Cash Flow | -$0 | -$0 | -$0 | -$0 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | -$0 | -$0 | -$0 | -$0 |